CMAX in English translation

• cmax
• respectively

Examples of using Cmax in Slovak and their translations into English

Súbežné podávanie rifampicínu s trabektedínom viedlo k zníženej plazmatickej expozícii trabektedínu o približne 22% pri Cmax a 31% pri AUC.
When rifampicin was co-administered with trabectedin, it resulted in reduced plasma exposure of trabectedin by approximately 22% for Cmax and 31% for AUC.

Po podaní lieku Ruconest(50 jednotiek/kg) asymptomatickým pacientom s HAE sa pozorovalo Cmax= 1,36 jednotiek/ml.
After administration of Ruconest(50 U/kg) to asymptomatic HAE patients, a Cmax of 1.36 U/ml was observed.

Po subkutánnej bolusovej injekcii v dávke 0,14 mg/kg kladribínu sa Cmax 91 ng/ml v priemere dosahuje už po 20 minútach.
After subcutaneous bolus injection of a 0.14 mg/kg cladribine dose, a Cmax of 91 ng/ml is reached on average after 20 minutes only.

V malej farmakokinetickej štúdii boli Cmax a AUC prukalopridu v priemere o 10-20% vyššie u pacientov so stredne ťažkou
In a small pharmacokinetic study, the Cmax and AUC of prucalopride were, on average, 10-20% higher in patients with

Omeprazol podávaný v dávkach 40 mg zdravým jedincom v skríženej štúdii zvýšil Cmax cilostazolu o 18%
Omeprazole, given in doses of 40 mg to healthy subjects in a cross-over study, increased Cmax and AUC for cilostazol by 18%

Hodnota Cmax ceritinibu v rovnovážnom stave v odporúčanej klinickej dávke 750 mg denne môže prevýšiť Ki hodnoty CYP3A
The steady-state Cmax value of ceritinib at the recommended clinical dose of 750 mg daily may exceed the Ki values for CYP3A

zvýšilo AUC repaglinidu 8,1-násobne a Cmax 2,4-násobne.
increased the repaglinide AUC 8.1-fold and Cmax 2.4-fold in healthy volunteers.

ale znížil jeho Cmax o 34% až 46%.
but decreased the Cmax by 34% to 46%.

Po podaní supraterapeutickej dávky 10 mg linagliptínu súbežne so 40 mg simvastatínu denne počas 6 dní sa zvýšila plazmatická AUC simvastatínu o 34% a plazmatická Cmax o 10%.
Following administration of a supratherapeutic dose of 10 mg linagliptin concomitantly with 40 mg of simvastatin daily for 6 days, the plasma AUC of simvastatin was increased by 34%, and the plasma Cmax by 10%.

tadalafilu(10 mg) 2- násobne a Cmax o 15% v porovnaní s hodnotami AUC a Cmax pre samotný tadalafil.
2-fold and Cmax by 15%, relative to the AUC and Cmax values for tadalafil alone.

V štúdii s pacientmi s diabetom mellitus 2. typu po subkutánnom podaní 0,2 jednotky/kg inzulínu glulizínu, Cmax bol 91 μJednotiek/ml s interkvartilným rozsahom od 78 do 104 μJednotiek/ml.
In a study in patients with type 2 diabetes mellitus after subcutaneous administration of 0.2 Units/kg insulin glulisine, the Cmax was 91 µUnits/ml with the interquartile range from 78 to 104 µUnits/ml.

nemalo žiadny vplyv na Cmax.
had no impact on Cmax.

ťažkou poruchou funkcie pečene sa AUCinf zvýšila o 60% a 79%, Cmax sa zvýšila o 67%
severe hepatic impairment, AUCinf was increased 60% and 79%, Cmax was increased 67%

po jednorazovej dávke 2- násobne a Cmax o 15% v porovnaní s hodnotami AUC a Cmax pre samotný tadalafil.
2-fold and Cmax by 15%, relative to the AUC and Cmax values for tadalafil alone.

nateglinid vykazoval lineárnu farmakokinetiku pre AUC aj Cmax, pričom tmax nezávisel od dávky.
nateglinide showed linear pharmacokinetics for both AUC and Cmax, and tmax was independent of dose.

zvýšeniu hodnoty AUC dabrafenibu, ale nezmenilo Cmax dabrafenibu v porovnaní s podávaním samotného dabrafenibu 75 mg dvakrát denne.
did not alter dabrafenib Cmax relative to administration of dabrafenib 75 mg twice daily alone.

k 33% zvýšeniu Cmax dabrafenibu v porovnaní s podávaním samotného dabrafenibu 75 mg dvakrát denne.
a 33% increase in dabrafenib Cmax relative to administration of dabrafenib 75 mg twice daily alone.

Súbežné podávanie saxagliptínu so stredne silným inhibítorom CYP3A4/5 diltiazemom zvýšilo Cmax saxagliptínu o 63%
Concomitant administration of saxagliptin with the moderate inhibitor of CYP3A4/5 diltiazem, increased the Cmax and AUC of saxagliptin by 63%

Súbežné podávanie saxagliptínu so silným inhibítorom CYP3A4/5 ketokonazolom zvýšilo Cmax saxagliptínu o 62%
Concomitant administration of saxagliptin with the potent inhibitor of CYP3A4/5 ketoconazole, increased the Cmax and AUC of saxagliptin by 62%

znížil Cmax(maximálna koncentrácia v plazme)
decreased the Cmax(maximum plasma concentration)